Protara Therapeutics, Inc. reported a net loss of $11.2 million, or 50 cents per share, for the third quarter ended September 30, 2024. As a clinical-stage company, Protara does not generate product revenue, and losses are typical due to ongoing research and development investments.
The company provided updates on its clinical pipeline, stating it was on track to report interim data from six-month evaluable patients in the ADVANCED-2 trial of TARA-002 in Non-Muscle Invasive Bladder Cancer (NMIBC) in the fourth quarter of 2024. Additionally, interim 12-month data from the ADVANCED-2 trial is expected in mid-2025.
Protara also noted encouraging results and general tolerability for TARA-002 in the first cohort of the Phase 2 STARBORN-1 trial for pediatric Lymphatic Malformations (LMs), with initial results from the next cohort anticipated in the first half of 2025. The company also highlighted the recent Fast Track designation received from the U.S. FDA for IV Choline Chloride.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.